British Pharmacopoeia

Naproxen Oral Suspension – BP 2022

These chromatograms are provided for information only as an aid to analysts and are intended as guidance for the interpretation and application of BP monographs.

Typical chromatogram for solution (3) in the Related Substances test for Naproxen Oral Suspension as published in BP 2022.



Peak ID: 1: Impurity O; 2: Impurity K; 3: Naproxen; 4: Impurity L; 5: Impurity N

The correction factor for impurity N is 1.0, not 1.5 as stated in the monograph. The relative retention of impurity N is about 5.6, not 4.5 as stated in the monograph. The monograph will be corrected in the BP 2023.

Column	:	Nucleosil 120-3 C18 (100 mm X 4.0 mm, 3.0 µm)
Method Ref.	:	Related Substances for the Naproxen Oral Suspension monograph from BP 2022
Mobile Phase	:	Acetonitrile: buffer (42: 58, v/v)
Buffer	:	0.01 M potassium dihydrogen orthophosphate adjusted to pH 2.0 with orthophosphoric acid.
Diluent	:	Mobile phase
Flow rate	:	1.5 mL/min
Column Temp	:	50 °C
Injection Volume	:	20 µL
Detection	:	230 nm

MHRA

Typical chromatogram for solution (2) in the Assay test for Naproxen Oral Suspension as published in BP 2022.



Peak ID: 1: Naproxen

Column	:	Nucleosil 120-3 C18 (100 mm X 4.0 mm, 3.0 µm)
Method Ref.	:	Assay for the Naproxen Oral Suspension monograph from BP 2022
Mobile Phase	:	Acetonitrile: buffer (42: 58, v/v)
Buffer	:	0.01 M potassium dihydrogen orthophosphate adjusted to pH 2.0 with orthophosphoric acid.
Diluent	:	Mobile phase
Flow rate	:	1.5 mL/min
Column Temp	:	50 °C
Injection Volume	:	20 µL
Detection	:	230 nm